P N O C 0 2 7 2 0 2 5
A C O M B I N E D
P H A S E 2 T R I A L
Expanding the Frontiers of Personalized Medicine: PNOC027 Phase 2 Trial
This approach seeks to reduce toxicity and avoid ineffective therapies, while personalizing care in a way that better meets the needs of children with relapsed brain cancers.
The Combined Phase 2 Trial: Medulloblastoma and Ependymoma
After completing a feasibility study for medulloblastoma, PNOC027 is now preparing for a Phase 2 trial that includes both medulloblastoma and ependymoma. Each trial arm will enroll approximately 30 children, offering an opportunity to refine and validate real-time drug screening and genomic testing as tools to guide treatment for relapsed cancers.
Expanding the trial to include ependymoma reflects PNOC’s commitment to addressing unmet needs in pediatric oncology. Ependymoma, like medulloblastoma, is a complex brain cancer with limited treatment options after relapse. Its unique biology and the availability of tissue from surgical re-resections make it well-suited to PNOC027’s precision medicine approach.
halfway there.
To reach the finish line, we need to raise an additional $300,000 by mid-2025 These funds will support the enrollment and treatment of 60 children 30 in each trial arm at an estimated cost of $10,000 per patient.
Timeline:
The trial is currently awaiting final approval, and patient enrollment is expected to begin in January 2025. The next few months are critical to ensuring we are fully funded and prepared to move forward on schedule
Join Us Now in Supporting Children with Brain Cancer:
PNOC027 represents a meaningful step forward in addressing the challenges of treating relapsed pediatric brain cancers. By supporting this effort, you can contribute to an initiative that seeks to expand treatment options and improve care for children with some of the most difficult-to-treat cancers.
With your help, we can continue advancing precision medicine in pediatric oncology, offering hope for children today and building a foundation for better outcomes in the future
PNOC FOUNDATION
